Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -113.81% is in line with its 5-year average of -114.33%, around the middle of its 5-year range (-300.34%–-12.04%).
6.88% above its 12-month average of -122.22%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -28.68%.
RETURN ON ASSETS (ROA)
-113.81%
RETURN ON ASSETS (ROA) AVG TTM
-122.22%
RETURN ON ASSETS (ROA) AVG 3Y
-139.21%
RETURN ON ASSETS (ROA) AVG 5Y
-114.33%
RETURN ON ASSETS (ROA) AVG 10Y
-75.62%
RETURN ON ASSETS (ROA) AVG 15Y
-46.41%
RETURN ON ASSETS (ROA) AVG 20Y
-40.44%
CURRENT VS TTM AVG
+6.88%
CURRENT VS 3Y AVG
+18.24%
CURRENT VS 5Y AVG
+0.45%
CURRENT VS 10Y AVG
-50.50%
CURRENT VS 15Y AVG
-145.21%
CURRENT VS 20Y AVG
-181.42%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-253.01%
vs the sector median at left
Summit Therapeutics Inc.
Market Cap
$13.81B
Return on Assets (ROA)
-113.81%
TTM Avg
-122.22%
3Y Avg
-139.21%
5Y Avg
-114.33%
Market Cap
$14.04B
Return on Assets (ROA)
33.29%
TTM Avg
-24.43%
3Y Avg
-40.18%
5Y Avg
-39.80%
Market Cap
$13.11B
Return on Assets (ROA)
-57.20%
TTM Avg
-68.10%
3Y Avg
-82.79%
5Y Avg
-75.08%
Market Cap
$14.54B
Return on Assets (ROA)
8.49%
TTM Avg
0.81%
3Y Avg
0.80%
5Y Avg
0.69%
Market Cap
$13.01B
Return on Assets (ROA)
16.05%
TTM Avg
17.04%
3Y Avg
15.32%
5Y Avg
20.00%
Market Cap
$14.63B
Return on Assets (ROA)
13.16%
TTM Avg
9.75%
3Y Avg
8.43%
5Y Avg
10.25%
Market Cap
$14.66B
Return on Assets (ROA)
34.50%
TTM Avg
22.59%
3Y Avg
17.42%
5Y Avg
13.40%
Market Cap
$14.69B
Return on Assets (ROA)
-3.17%
TTM Avg
-0.94%
3Y Avg
2.58%
5Y Avg
3.75%
Market Cap
$12.93B
Return on Assets (ROA)
6.18%
TTM Avg
14.27%
3Y Avg
15.75%
5Y Avg
18.01%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | $13.81B | -113.81% | -122.22% | -139.21% | -114.33% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 33.29% | -24.43% | -40.18% | -39.80% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -57.20% | -68.10% | -82.79% | -75.08% |
| Jazz Pharmaceuticals plc (JAZZ)vs › | $14.54B | 8.49% | 0.81% | 0.80% | 0.69% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 16.05% | 17.04% | 15.32% | 20.00% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 13.16% | 9.75% | 8.43% | 10.25% |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 34.50% | 22.59% | 17.42% | 13.40% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | -3.17% | -0.94% | 2.58% | 3.75% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 6.18% | 14.27% | 15.75% | 18.01% |
| Tempus AI, Inc. (TEM)vs › | $12.61B | -10.75% | -43.49% | -42.71% | -41.26% |
ROA
-113.8%
ROE
-135.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -193.65% |
| 2024-12-31 | -50.79% |
| 2023-12-31 | -300.34% |
| 2022-12-31 | -12.04% |
| 2021-12-31 | -77.96% |
| 2020-12-31 | -51.18% |
| 2019-12-31 | -31.79% |
| 2019-01-31 | 13.67% |
| 2018-01-31 | -25.81% |
| 2017-01-31 | -45.49% |
| 2016-01-31 | -56.43% |
| 2015-01-31 | -38.95% |
| 2014-01-31 | -50.63% |
| 2013-01-31 | -61.11% |
| 2012-01-31 | -69.15% |
| 2011-01-31 | -92.12% |
| 2010-01-31 | -29.07% |
| 2009-01-31 | -160.69% |
| 2008-01-31 | -29.01% |
| 2007-01-31 | -12.76% |
| 2006-01-31 | -7.33% |
| 2005-01-31 | -0.32% |
| 2004-01-31 | -28.75% |
